EGFR and gastric cancer: We have also recently shown that MICAL-L2 attenuates lysosome-mediated EGFR degradation and enhances the migratory ability of gastric cancer cells, suggesting that MICAL-L2 functions to prevent the degradation of its client proteins and may play an oncogenic role in gastric cancer (Min et al., 2019).